Tim Smith

These data highlight the results of an international sample of adult patients with allergies to certain food products and caregivers of children with food allergies.

This analysis explores the burden level in pediatric and adolescent eczema patients within Japan, highlighting associated burden on caregivers/families and other factors.

These findings were referenced by skincare brand CeraVe, highlighting the need for skin health education as well as skin health barriers.

These data suggest differences in Medicaid-accepting pediatric dermatologist access based on such factors as geographic area and density of pediatric dermatologists per county.

This summary of major dermatology news covered in June highlights stories such as late-breaking data at RAD 2024, recent interviews, and recent FDA news.

The case series highlighted here was limited due to smaller numbers of participants, necessitating additional real-world data on bimekizumab for psoriasis.

These real-world findings on tildrakizumab’s use among patients with moderate-to-severe plaque psoriasis highlight the drug’s efficacy regarding high burden symptoms.

In this analysis, disparities associated with race, old age, socioeconomic differences, and rural residence were highlighted as examples.

This analysis looked at children 1 to 11 years of age with eosinophilic esophagitis, highlighting the impacts of dupilumab on EoE.

These findings made comparisons between clinical outcomes of interclass and intraclass switching of biologic treatments among individuals with psoriasis.

These data were identified to expand upon existing information regarding treatment options for facial psoriasis and/or genital psoriasis.

Following this post-hoc analysis, additional research may be necessary to assess other safety implications of a dose increase of abrocitinib for atopic dermatitis patients prior to Week 12.

These data suggest that quality of life, assessed by DLQI, may be implemented in determining treatment efficacy among patients with psoriasis.

These data, resulting from a post-hoc analysis, highlighted the musculoskeletal, skin, and nail outcomes among patients with psoriasis and PsA.

The announcement follows the release of the RhodoLED XL red light-emitting lamp, to be used in combination with aminolevulinic acid hydrochloride topical gel, 10% for actinic keratoses

This analysis among Japanese patients highlights the potential of apremilast for psoriasis patients not responding to topical therapy who may have limited systemic treatment options.

These data highlight the efficacy of ritlecitinib for patients with alopecia areata and extensive hair loss at baseline.

These data demonstrate a unique dichotomy between 2 trends associated with gender gaps in the field of dermatology.

In this systematic review and meta-analysis, the clinical efficacy of glucagon-like peptide 1 receptor agonists was evaluated.

These data highlight rates of biologic treatment discontinuation in younger adult patients versus elderly patients, with comparisons drawn between IL-23 inhibitors and IL-17 inhibitors as well.

These data do not support the idea that interferon-beta works as a trigger for psoriasis, though it may have a different influence on psoriasis among those with MS versus those without MS.

This analysis highlights the potential for abrocitinib as an alternative to biologics in the eczema treatment armamentarium.

These data highlight the patterns of treatment as well as prevalence of LPP within the US.

These data resulted from a new meta-analysis in which biologic therapies were shown to be less effective among psoriasis patients with clinical characteristics such as age and BMI.

These data highlight the benefits of utilizing the WI-NRS as an instrument for supporting efficacy endpoints assessing pruritus intensity among prurigo nodularis patients.

These data may require large-scale studies to duplicate the findings, evaluating individuals with psoriasis who had PPM for IE antibiotic prophylaxis.

These data improve existing definitions of the spectrum of cutaneous manifestations reported by patients with VEXAS.

These data, presented at RAD 2024, highlight the potential of delgocitinib cream for patients with chronic hand eczema in terms of patient and clinician reported outcomes.

The FDA provided 510(k) clearance for the COR-12 wireless ECG device, which was now integrated with the SpiroSphere.

These data highlighted which drug, in combination with topical corticosteroids, produced the best efficacy results for those with atopic dermatitis.